OBJECTIVE: To evaluate the safety and efficacy of contact transcleral ciliary body photodynamic treatment (CB-PDT) with verteporfin in human eyes. DESIGN: Prospective interventional case series. PARTICIPANTS: Five glaucomatous blind eyes of 5 patients. METHODS: Verteporfin (6 mg/m(2)) was infused in bolus and then the ciliary body was irradiated transclerally with a fibre optic device. Twelve spots were placed 360° and 0.5 mm behind the sclerocorneal limbus. Laser power was 80 mW and irradiation time was 3 minutes. RESULTS: The average intraocular pressure reduction was 30% after the first month and remained below pre-treatment levels throughout a 3-month follow-up. No serious adverse events were reported. CONCLUSIONS: CB-PDT for refractory glaucoma was safe and efficient in human eyes; larger studies are required to evaluate its possible clinical role.
OBJECTIVE: To evaluate the safety and efficacy of contact transcleral ciliary body photodynamic treatment (CB-PDT) with verteporfin in human eyes. DESIGN: Prospective interventional case series. PARTICIPANTS: Five glaucomatous blind eyes of 5 patients. METHODS:Verteporfin (6 mg/m(2)) was infused in bolus and then the ciliary body was irradiated transclerally with a fibre optic device. Twelve spots were placed 360° and 0.5 mm behind the sclerocorneal limbus. Laser power was 80 mW and irradiation time was 3 minutes. RESULTS: The average intraocular pressure reduction was 30% after the first month and remained below pre-treatment levels throughout a 3-month follow-up. No serious adverse events were reported. CONCLUSIONS: CB-PDT for refractory glaucoma was safe and efficient in human eyes; larger studies are required to evaluate its possible clinical role.
Authors: Anna I Dastiridou; Andreas Katsanos; Philippe Denis; Brian A Francis; Dimitrios G Mikropoulos; Miguel A Teus; Anastasios-Georgios Konstas Journal: Adv Ther Date: 2018-11-17 Impact factor: 3.845